266 articles with Ablynx
Dr Bo Jesper Hansen has decided to resign from the Board of Directors with immediate effect for personal reasons.
Only a week after Sanofi ponied up $11.6B to buy Waltham, Massachusetts-based Bioverativ, the French drugmaker is buying Ghent, Belgium-based Ablynx for $4.8B.
Novo has tried to apply pressure, but the ABLX board and principal shareholder have not been moved.
Dr Friesen has more than 20 years of experience in the biopharmaceutical industry, leading multiple Research and Development (R&D) organisations.
As a result of these transactions, Ablynx now has a share capital of €140,320,046.59 represented by a total number of 75,065,990 shares, conferring a total number of 75,065,990 voting rights.
Ablynx: Publication In Accordance With Article 14 Of The Belgian Law Of 2 May 2007 Regarding The Publication Of Major Shareholdings (The "Transparency Law") – Jan. 18, 2018
The notifications contain the following information:
Ablynx: Publication in Accordance With Article 14 of the Belgian Law of 2 May 2007 Regarding the Publication of Major Shareholdings (the "Transparency Law") – Jan. 16, 2018
Van Herk Investments B.V. notified Ablynx that it has crossed the 10% threshold on 12 January 2018 and now holds 7,629,229 voting securites of Ablynx.
Ablynx: Publication In Accordance With Article 14 of The Belgian Law Of 2 May 2007 Regarding The Publication of Major Shareholdings (The "Transparency Law") - Jan. 10, 2018
The company received a notification of shareholdings from Consonance CapMan GP LLC on 5 January 2018.
The offers underline Novo Nordisk's interest in expanding beyond diabetes and into the rare diseases market.
Will this new buy be enough for Celgene investors?
Ablynx today announced that Dr Peter Fellner, who has served as Chairman since 2013, has decided to resign from the Board with immediate effect.
Ablynx today announced that it will present at the 36th Annual J.P. Morgan Healthcare Conference on Monday 8 January 2018 at 09:30 a.m. Pacific Standard Time (06:30 p.m. Central European Time).
The waiver will take effect on 29 December 2017 and the securities may be sold on or after such date.
Ablynx today announced that the single and multiple dose Phase I study demonstrated comparable PK of caplacizumab in Japanese and Caucasian subjects.
Ablynx Reports Additional Clinically Important Benefits of Caplacizumab From Its Phase III Hercules Study in Acquired TTP
These new data relate to additional pre-specified secondary endpoints and demonstrate that treatment with caplacizumab resulted in a clinically meaningful reduction in the use of PEX and length of stay in the ICU and the hospital.
Ablynx Will Host a Webcast to Discuss Additional Data From its Phase III Hercules Study of Caplacizumab in Acquired TTP Following ASH Late-Breaking Data Presentation
The late-breaking data presentation will include positive topline results from the Phase III HERCULES study of caplacizumab announced on 2 October 2017 together with important data from additional analyses on the use of plasma exchange.
Ablynx: Publication In Accordance With Article 14 Of The Belgian Law Of 2 May 2007 Regarding The Publication Of Major Shareholdings (The "Transparency Law") – Nov. 29, 2017
Millennium Group Management LLC notified Ablynx that it has crossed downward the lowest threshold on 21 November 2017.
Ablynx: Results From the Phase III Hercules Study of Caplacizumab for the Treatment of Acquired TTP Selected For Presentation in the Late-Breaking Abstracts Session at the 2017 ASH Annual Meeting
Positive topline results from the Phase III HERCULES study, meeting primary and two key secondary endpoints, were announced on 2 October 2017.
Revenues of €44.7 million (2016: €68.9 million).
Ablynx: Publication in Accordance With Article 14 of The Belgian Law of 2 May 2007 Regarding The Publication of Major Shareholdings (The "Transparency Law") - Nov. 10, 2017
The company received a notification of shareholdings from Millennium Group Management LLC on 7 November 2017.